Related Experiment Video
Updated: Jul 16, 2026
08:35
A Human Glioblastoma Organotypic Slice Culture Model for Study of Tumor Cell Migration and Patient-specific Effects of Anti-Invasive Drugs
Published on: July 20, 2017
Glioblastoma Subtypes Exhibit Distinct Migration Mechanics and Immune Responses
Ghaidan A Shamsan1, Chao J Liu1, Brooke C Braman1
1Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota.
Cancer Research Communications
|July 14, 2026
Summary
Mesenchymal glioblastoma cells migrate faster but are counteracted by a protective immune response, leading to longer survival. This immune
Area of Science:
- Neuro-oncology
- Cancer Biology
- Cell Migration
Background:
- Glioblastoma is a fatal brain cancer characterized by tumor cell invasion.
- Molecular subtypes exist, but their mechanistic and clinical differences are unclear.
- Understanding subtype-specific behaviors is crucial for targeted therapies.
Purpose of the Study:
- To investigate the mechanistic differences in migration and immune response between glioblastoma subtypes.
- To correlate these differences with clinical outcomes and survival rates.
Main Methods:
- Utilized the motor-clutch model to analyze cell migration dynamics.
- Compared mesenchymal and proneural glioma cell behavior in vitro and in brain tissue.
- Assessed tumor growth and survival in immunocompetent and immunodeficient mouse models.
Main Results:
- Mesenchymal glioma cells exhibit increased spread, traction forces, and faster migration compared to proneural cells.
- Mice with mesenchymal tumors showed longer survival, linked to a T cell-mediated immune response.
- Tumor induction in immunodeficient mice revealed shorter survival for mesenchymal tumors, confirming a protective immune role.
Conclusions:
- Mesenchymal glioblastoma displays aggressive migration counterbalanced by an immunologically 'hot' environment that suppresses proliferation.
- These opposing forces may explain the observed clinical survival similarities between subtypes.
- Findings suggest potential for subtype-specific immunotherapies to improve glioblastoma treatment.
